GlassScriptPhysician profile
Katelin Thompson
NPI 1194202614
$3,575.53
in general payments reported to CMS, 2019-2025
29 companies · $1,821 in 2025
The $1,821 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $306 · 2023: $246 · 2024: $1,056 · 2025: $1,821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,011 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,010.78 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $627.15 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $436.73 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $390.55 | 2024-2025 | Rexulti |
| Corium, LLC | $289.59 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $236.67 | 2024-2025 | Caplyta |
| Alkermes, INC. | $154.28 | 2024-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $152.24 | 2025 | Austedo Xr |
| Collegium Pharmaceutical, INC. | $138.23 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $123.66 | 2024-2025 | Fanapt |
| Novo Nordisk INC | $118.28 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $109.18 | 2024-2025 | Cobenfy |
| Lilly USA, LLC | $99.23 | 2021-2024 | Mounjaro, Kisunla, Jardiance |
| Almatica Pharma LLC | $88.85 | 2024-2025 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $78.86 | 2024 | |
| Neos Therapeutics, LP | $69.52 | 2023-2025 | Adzenys Xr-Odt, Exxua |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $63.65 | 2024-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $51.59 | 2021-2023 | |
| Pfizer INC. | $49.71 | 2021-2023 | |
| Dexcom, INC. | $44.29 | 2022-2023 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $41.11 | 2024 | Qelbree |
| Neurocrine Biosciences, INC. | $31.80 | 2025 | |
| Glaxosmithkline, LLC. | $30.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $30.33 | 2023 | |
| Boston Scientific Corporation | $27.97 | 2022-2023 | Watchman |
| Abbott Laboratories | $23.29 | 2021 | |
| Becton, Dickinson and Company | $22.58 | 2025 | Hemosphere |
| Astrazeneca Pharmaceuticals LP | $16.12 | 2024 | Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $15.51 | 2021 | |
| Amgen INC. | $14.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelin Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.